本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Syntara Ltd

0.064
-0.001-1.54%
成交量:178.85万
成交额:11.19万
市值:1.04亿
市盈率:-7.24
高:0.065
开:0.064
低:0.061
收:0.065
数据加载中...

公司资料

公司名字:
Syntara Ltd
交易所:
ASX
成立时间:
1998
员工人数:
- -
公司地址:
20A Rodborough Road,Unit 2,Frenchs Forest,New South Wales,Australia
邮编:
2086
传真:
61 2 9451 3622
简介:
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company's drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, pulmonary fibrosis, liver, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO/MPO inhibitor programs. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.